NeOnc Technologies Appoints Dr. David M. Ashley, Director of The Preston Robert Tisch Brain Tumor Center at Duke, to Scientific Advisory Board
NeOnc Technologies (NTHI), a clinical-stage biopharmaceutical company focused on CNS cancer therapies, has appointed Dr. David M. Ashley to its Scientific Advisory Board. Dr. Ashley serves as the Director of The Preston Robert Tisch Brain Tumor Center at Duke University and holds the position of Rory David Deutsch Distinguished Professor of Neuro-Oncology.
Dr. Ashley brings significant expertise in brain tumor immunology and epigenetics, with experience in both pediatric and adult brain cancers. His appointment is expected to strengthen NeOnc's pipeline, particularly the development of lead candidates NEO100™ and NEO212™. Since 2018, he has led one of North America's largest dedicated brain tumor centers, integrating clinical care, translational research, and education.
NeOnc Technologies (NTHI), una società biofarmaceutica in fase clinica focalizzata sulle terapie per i tumori CNS, ha nominato Dr. David M. Ashley nel suo Consiglio Scientifico Consultivo. Il Dr. Ashley è Direttore del The Preston Robert Tisch Brain Tumor Center presso la Duke University e ricopre la posizione di Rory David Deutsch Distinguished Professor of Neuro-Oncology.
Il Dr. Ashley apporta una notevole expertise in immunologia dei tumori cerebrali ed epigenetica, con esperienza sia in tumori cerebrali pediatrici che adulti. La sua nomina dovrebbe rafforzare la pipeline di NeOnc, in particolare lo sviluppo dei lead candidate NEO100™ e NEO212™. Dal 2018 dirige uno dei più grandi centri di tumori cerebrali dell'America settentrionale, integrando assistenza clinica, ricerca traslazionale ed istruzione.
NeOnc Technologies (NTHI), una empresa biofarmacéutica en etapa clínica centrada en terapias para el sistema nervioso central (SNC) cancer, ha nombrado al Dr. David M. Ashley en su Junta Asesora Científica. El Dr. Ashley se desempeña como Director del The Preston Robert Tisch Brain Tumor Center en la Duke University y ostenta la posición de Rory David Deutsch Distinguished Professor of Neuro-Oncology.
El Dr. Ashley aporta una experiencia significativa en inmunología de tumores cerebrales y epigenética, con experiencia tanto en tumores cerebrales pediátricos como en adultos. Se espera que su nombramiento fortalezca la cartera de NeOnc, particularmente el desarrollo de los candidatos principales NEO100™ y NEO212™. Desde 2018, ha dirigido uno de los centros de tumores cerebrales más grandes de Norteamérica, integrando atención clínica, investigación traslacional y educación.
NeOnc Technologies (NTHI)는 CNS 암 치료에 집중하는 임상 단계의 생물의약 기업으로, 과학 자문위원회에 Dr. David M. Ashley를 임명했습니다. Ashley 박사는 듀크 대학교의 Preston Robert Tisch Brain Tumor Center의 이사이며 Neuro-Oncology의 Rory David Deutsch 저명 교수 직위를 보유하고 있습니다.
Ashley 박사는 뇌종양 면역학 및 에피제네틱스 분야의 풍부한 전문 지식을 보유하고 있으며, 소아 및 성인 뇌암 경험이 있습니다. 그의 임명은 NeOnc의 파이프라인을 강화하고 특히 주력 후보군 NEO100™ 및 NEO212™의 개발에 기여할 것으로 예상됩니다. 2018년부터 북미에서 가장 큰 뇌종양 센터 중 하나를 이끌며 임상 치료, 번역 연구 및 교육을 통합하고 있습니다.
NeOnc Technologies (NTHI), société biopharmaceutique en phase clinique spécialisée dans les thérapies pour les cancers du système nerveux central (SNC), a nommé Dr. David M. Ashley au sein de son Conseil consultatif scientifique. Le Dr. Ashley est le Directeur du The Preston Robert Tisch Brain Tumor Center à l’Université Duke et occupe le poste de Rory David Deutsch Distinguished Professor of Neuro-Oncology.
Le Dr. Ashley apporte une expertise significative en immunologie des tumeurs cérébrales et en épigénétique, avec une expérience dans les cancers cérébraux pédiatriques et adultes. Sa nomination devrait renforcer le portefeuille de NeOnc, en particulier le développement des candidats principaux NEO100™ et NEO212™. Depuis 2018, il dirige l’un des plus grands centres de tumeurs cérébrales d’Amérique du Nord, intégrant soins cliniques, recherche translationnelle et éducation.
NeOnc Technologies (NTHI), ein klinisch entwickelndes Biopharma-Unternehmen, das sich auf Therapien gegen CNS-Krebs spezialisiert hat, hat Dr. David M. Ashley in seinen Wissenschaftlichen Beirat berufen. Dr. Ashley dient als Direktor des Preston Robert Tisch Brain Tumor Center an der Duke University und bekleidet die Position des Rory David Deutsch Distinguished Professor der Neuro-Onkologie.
Dr. Ashley bringt erhebliche Expertise in der Immunologie von Hirntumoren und Epigenetik mit, mit Erfahrungen sowohl in pädiatrischen als auch in erwachsenen Hirntumoren. Seine Ernennung soll NeOncs Pipeline stärken, insbesondere die Entwicklung der Leitkandidaten NEO100™ und NEO212™. Seit 2018 leitet er eines der größten dedizierten Hirntumor-Zentren Nordamerikas und integriert klinische Versorgung, translational Forschung und Bildung.
NeOnc Technologies (NTHI)، وهي شركة أدوية حيوية في مرحلة سريرية تركّز على علاجات سرطان الجهاز العصبي المركزي، قد عيّنت Dr. David M. Ashley في مجلسها الاستشاري العلمي. يعمل الدكتور آشلي كمدير لمركز تيس Brain Tumor في جامعة دوك ويحمل رتبة Rory David Deutsch Distinguished Professor of Neuro-Oncology.
يجلب الدكتور آشلي خبرة كبيرة في علم المناعة لأورام الدماغ والوراثة التنظيمية Epigenetics، مع خبرة في كل من أورام الدماغ للأطفال والبالغين. من المتوقع أن تقوي تعيينه خط NeOnc، وتحديداً تطوير المرشحين الرائد NEO100™ و NEO212™. منذ 2018، يقود واحداً من أكبر مراكز أورام الدماغ المكرسة شمال أمريكا، مدمجاً الرعاية السريرية والبحوث الترابطية والتعليم.
NeOnc Technologies (NTHI)，是一家处于临床阶段的生物制药公司，专注于中枢神经系统癌症治疗，现任命 Dr. David M. Ashley 为其科学顾问委员会成员。Ashley博士担任杜克大学 Preston Robert Tisch Brain Tumor Center 的主任，并担任 Neuro-Oncology 的 Rory David Deutsch Distinguished Professor。
Ashley博士在脑肿瘤免疫学和表观遗传学方面具有丰富专业知识，对儿科和成人脑肿瘤均有经验。此任命预计将增强NeOnc的管线，特别是领先候选药物 NEO100™ 和 NEO212™ 的开发。自2018年以来，他一直领导北美最大的专门脑肿瘤中心之一，整合临床护理、转化研究与教育。
- None.
- None.
CALABASAS, Calif., Oct. 02, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, today announced it has appointed Dr. David M. Ashley to its scientific advisory board. Dr. Ashley is the Rory David Deutsch Distinguished Professor of Neuro-Oncology and the Director of The Preston Robert Tisch Brain Tumor Center at Duke University.
Amir F. Heshmatpour, Executive Chairman & President, of NeOnc Technologies, commented, “We are privileged to have Dr. David M. Ashley MBBS (Hons), FRACP, PhD, of Duke University on NeOnc’s Scientific Advisory Board. Dr. Ashley is one of the world’s foremost leaders in neuro-oncology, with groundbreaking work in brain tumor immunology and epigenetics and decades of experience across both pediatric and adult brain cancers. His proven ability to translate laboratory discoveries into first-in-human studies will directly strengthen our pipeline, including our lead candidates NEO100™ and NEO212™.
“As we expand our SAB with distinguished key opinion leaders from across the United States, Dr. Ashley exemplifies the level of world-class expertise guiding NeOnc forward in our mission to deliver new, life-changing treatments for patients and families battling brain cancer.”
David M. Ashley, MBBS (Hons), FRACP, PhD, Duke University
David M. Ashley is the Rory David Deutsch Distinguished Professor of Neuro-Oncology and Director of The Preston Robert Tisch Brain Tumor Center at Duke, positions he has held since 2018 after joining from Australia, where he trained and led major neuro-oncology programs. He practices adult and pediatric neuro-oncology and oversees one of North America’s largest dedicated brain tumor centers, integrating clinical care, translational research, and education. His scholarship spans CNS tumor biology, immuno-oncology, and clinical trials, and he has served as principal investigator on national and international studies that inform current practice. Dr. Ashley’s cross-continental career and leadership of a globally recognized brain-tumor center have earned him a strong international reputation for advancing patient-centered innovation in neuro-oncology.
ABOUT NEONC TECHNOLOGIES HOLDINGS, INC.
NeOnc Technologies Holdings, Inc. is a clinical-stage life sciences company focused on the development and commercialization of central nervous system therapeutics that are designed to address the persistent challenges in overcoming the blood-brain barrier. The company’s NEO™ drug development platform has produced a portfolio of novel drug candidates and delivery methods with patent protections extending to 2038. These proprietary chemotherapy agents have demonstrated positive effects in laboratory tests on various types of cancers and in clinical trials treating malignant gliomas. NeOnc’s NEO100™ and NEO212™therapeutics are in Phase II human clinical trials and are advancing under FDA Fast-Track and Investigational New Drug (IND) status. The company has exclusively licensed an extensive worldwide patent portfolio from the University of Southern California consisting of issued patents and pending applications related to NEO100, NEO212, and other products from the NeOnc patent family for multiple uses, including oncological and neurological conditions.
For more about NeOnc and its pioneering technology, visit neonc.com.
Important Cautions Regarding Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by terminology such as “may,” “will,” “should,” “intend,” “expect,” “plan,” “budget,” “forecast,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “evaluating,” or similar words. Statements that contain these words should be read carefully, as they discuss our future expectations, projections of future results of operations or financial condition, or other forward-looking information.
Examples of forward-looking statements include, among others, statements regarding whether a definitive agreement will be reached with Quazar. These statements reflect our current expectations based on information available at this time, but future events may differ materially from those anticipated.
The “Risk Factors” section of our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, along with other cautionary language in that report or in our subsequent filings, outlines important risks and uncertainties. These may cause our actual results to differ materially from the forward-looking statements herein, including but not limited to the failure to finalize the agreement with Quazar, modifications to its terms, or alternative uses of proceeds.
We assume no obligation to revise or update any forward-looking statements, whether as a result of new information, future developments, or otherwise, except as required by applicable securities laws and regulations.
“NEO100” and NEO “212” are registered trademarks of NeOnc Technologies Holdings, Inc.
Company Contact:
info@neonc.com
Investor Contact:
James Carbonara
Hayden IR
(646)-755-7412
James@haydenir.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/84071892-417d-42f7-9753-89b7ab58bb21
FAQ
Who is Dr. David M. Ashley and what is his role at NeOnc Technologies (NTHI)?
What expertise does Dr. Ashley bring to NeOnc Technologies (NTHI)?
How will Dr. Ashley's appointment impact NeOnc Technologies' (NTHI) drug development?
What is Dr. Ashley's current position at Duke University?
What are NeOnc Technologies' (NTHI) main drug candidates?
